Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study

Palmer, D. H., Hawkins, N. S. , Vilgrain, V., Pereira, H., Chatellier, G. and Ross, P. J. (2019) Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncology, 16(1), pp. 4315-4325. (doi: 10.2217/fon-2019-0658) (PMID:31797680)

[img]
Preview
Text
205002.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

1MB

Abstract

Aim: To determine whether a liver tumor burden ≤25% and well-preserved liver function (albumin-bilirubin grade 1) are appropriate criteria for identifying patients with unresectable hepatocellular carcinoma who may benefit from selective internal radiation therapy (SIRT) using 90yttrium resin microspheres versus sorafenib. Patients & methods: Post-hoc analysis of patients in the intention-to-treat population of the SARAH trial (SIRT vs sorafenib) with ≤25% tumor burden and albumin-bilirubin grade 1. Primary end point: overall survival. Results: Median overall survival was 21.9 months (95% CI: 15.2–32.5, n = 37) with SIRT and 17.0 months (11.6–20.8, n = 48) with sorafenib (hazard ratios: 0.73; 95% CI: 0.44–1.21; p = 0.22). Conclusion: A combination of good liver function and low tumor burden may be relevant for selection of hepatocellular carcinoma patients for SIRT.

Item Type:Articles
Additional Information:Acknowledgments: The authors acknowledge the SARAH trial group, who conducted the original trial, and their support in the preparation of this paper.
Keywords:90yttrium, albumin-bilirubin grade, hepatocellular carcinoma, resin microspheres, selective internal radiation therapy, SIR-spheres, sorafenib, tumor burden.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Hawkins, Professor Neil
Authors: Palmer, D. H., Hawkins, N. S., Vilgrain, V., Pereira, H., Chatellier, G., and Ross, P. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Future Oncology
Publisher:Future Medicine
ISSN:1479-6694
ISSN (Online):1744-8301
Published Online:04 December 2019
Copyright Holders:Copyright © 2019 Daniel H Palmer
First Published:First published in Future Oncology 16(1):4315-4325
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record